

Org. No: 556966-4955  
October 12, 2022



## **Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy**

**Gothenburg, October 12, 2022 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next generation immuno-oncological treatments based on enhanced oncolytic viruses and CAR T-cells, today announced that the PhD thesis of the company's co-worker Jing Ma was awarded the best Swedish PhD thesis of the year within the field of gene and cell therapy for 2021 by the Swedish Society for Gene and Cell Therapy (SSGCT).**

Jing Ma's PhD thesis describes the development of Elicera's iTANK-platform and the upcoming CAR T-cell study in treatment of B-cell lymphoma. Jing Ma was invited to present her work at the SSGCT board meeting on October 11, 2022.

Jing Ma was supervised by Elicera Therapeutic's co-founder, Associate Professor Di Yu.

### **For further information please contact:**

Jamal El-Mosleh, CEO, Elicera Therapeutics AB  
Phone: +46 (0) 703 31 90 51  
[jamal.elmosleh@elicerca.com](mailto:jamal.elmosleh@elicerca.com)

### **About the iTANK platform**

*The iTANK- (immunoTherapies Activated with NAP for efficient Killing) platform is the company's own fully developed technology platform for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: tumor antigen heterogeneity and a hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating protein (NAP) from the bacterium *Helicobacter pylori*. Upon activation, NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of the CAR T-cell in addition to activating a parallel immune response via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK-platform is used to enhance the company's own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. More information about iTANK-platform is available here: <https://www.elicerca.com/technology>*

### **About Elicera Therapeutics AB**

*Elicera Therapeutics AB is a clinical stage cell and gene therapy company that develops next generation immuno-oncology treatments based on enhanced oncolytic viruses and CAR T-cells. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T-cells and two oncolytic viruses. In addition, Elicera has developed a technology platform called iTANK that can be used to optimize all CAR T-cells in development and activate killer T-cells against cancer. The company's share (ELIC) is traded on Nasdaq First North Growth Market. G&W Fondkommission has been appointed the Company's Certified Adviser. E-mail: [ca@gwkapital.se](mailto:ca@gwkapital.se), tel: +468-503 000 50.*

For more information, please visit [www.elicera.com](http://www.elicera.com)